Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -7.46%22 Debt-to-Equity is 0.02 as of Mar. 2026, which is 33% below its 10-year median of 0.03. GuruFocus rates BJDX with a GF Score™ of 22/100. Among 706 Medical Devices & Instruments companies, Bluejay Diagnostics ranks better than 92.07% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bluejay Diagnostics's Debt-to-Equity or its related term are showing as below:
BJDX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -20.34 Med: 0.03 Max: 0.12
Current: 0.02
During the past 7 years, the highest Debt-to-Equity Ratio of Bluejay Diagnostics was 0.12. The lowest was -20.34. And the median was 0.03.
BJDX's Debt-to-Equity is ranked better than 92.07% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs BJDX: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bluejay Diagnostics Debt-to-Equity Related Terms
Bluejay Diagnostics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Bluejay Diagnostics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJDX vs VTAK, PFSA, RBOT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Bluejay Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bluejay Diagnostics (BJDX) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bluejay Diagnostics and its competitors. This is 33% below median its historical median of 0.03. According to the industry distribution chart, Bluejay Diagnostics ranks #56 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 7.9%.
Is Bluejay Diagnostics' Debt-to-Equity too high?
Bluejay Diagnostics' current Debt-to-Equity of 0.02 is 33% below median its 10-year median of 0.03. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Bluejay Diagnostics' value of 0.02 is 91.3% below this industry median. Based on the distribution chart, Bluejay Diagnostics ranks #56 out of 706 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' Debt-to-Equity compare to VTAK and PFSA?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #56 out of 706 companies for Debt-to-Equity. This places Bluejay Diagnostics in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Bluejay Diagnostics' value of 0.02 is 91.3% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.23, Bluejay Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bluejay Diagnostics's current Debt-to-Equity of 0.02 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bluejay Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current Debt-to-Equity is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02, which is 33% below median its 10-year median of 0.03 and 91.3% below the Medical Devices & Instruments industry median of 0.23. Bluejay Diagnostics' overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
22GF Score
Get the complete analysis for BJDX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
